In this section:

08 October 2018

New Psoriatic Arthritis Treatment Approved in Scotland

The Scottish Medicines Consortium has today published its acceptance of ixekizumab (Taltz) as a treatment for psoriatic arthritis in Scotland.

Ixekizumab is accepted to treat psoriatic arthritis in the following circumstances:

Taltz binds to a cytokine (chemical messenger) called interleukin-17A (IL-17A), which is involved in the body’s inflammatory and immune responses. By binding to IL-17A, Taltz inhibits its action (ie. stops it from working as it usually does). This means Taltz interrupts the inflammatory cycle of psoriasis and psoriatic arthritis, which can lead to the improvement in symptoms for many people who take it.

Like other biologic treatments for psoriasis and psoriatic arthritis, Taltz is taken via injection. It is an immunosuppressive treatment – meaning it reduces the activity of part of the immune system thought to be involved in psoriasis. You can read more information on the action of Taltz, as well as its dosing regime and possible side effects by downloading our information sheet.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Registered Charity: 257414 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.